TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A chronic urticaria session at the American Academy of Dermatology meeting highlighted treatments aimed at BTK, c-KIT and the IL-4 receptor. Remibrutinib has been approved for chronic spontaneous urticaria, while reported phase III results and other therapies point to research extending into chronic inducible urticaria. The source does not provide detailed trial results or a timeline for further approvals.
A session at the American Academy of Dermatology meeting reviewed a widening range of treatment approaches for chronic hives, including BTK inhibition, c-KIT targeting and IL-4 receptor blockade. Brian Kim of the Icahn School of Medicine at Mount Sinai said the discussion covered approved treatment remibrutinib for chronic spontaneous urticaria (CSU), reported phase III results in several forms of chronic inducible urticaria (CIndU), and other therapies still under study.
In a video recorded after the meeting in April and published by MedPage Today on October 8, 2026, Kim described remibrutinib, marketed as Rhapsido, as a prominent topic. The source identifies it as a recently approved BTK inhibitor for CSU. Kim also referred to reported phase III data for CIndU covering dermatographism, cold urticaria and cholinergic urticaria. The report does not give trial sizes, specific outcomes, safety findings or regulatory decisions for those indications.
Kim also discussed dupilumab, which blocks the IL-4 receptor, and barzolvolimab, a c-KIT inhibitor. He said barzolvolimab may both inhibit and deplete mast cells; that characterization is his account of the drug’s proposed activity, not a detailed clinical finding in the report. Kim disclosed that he co-founded Alys Pharma, which is developing a c-KIT inhibitor using a bispecific strategy intended to target c-KIT on mast cells.
The session covered both CSU, in which hives arise spontaneously, and CIndU, in which symptoms are associated with particular triggers. The report presents these therapies as a mix of an approved treatment, clinical results and development approaches. It does not establish that every treatment discussed is available for every type of urticaria.
More Targets, Different Disease Forms
The range of approaches matters because CSU and CIndU are not interchangeable diagnoses, and the treatment evidence described in the report varies by condition. Remibrutinib is identified as approved for CSU, while the phase III CIndU findings are described as reported results without enough detail to judge their size or clinical importance. For patients and clinicians, that distinction is key: new targets can broaden research, but a meeting discussion alone does not establish a new standard of care.
The c-KIT and mast-cell strategies may also point research toward the cells involved in urticaria, while IL-4 receptor blockade represents another pathway being considered. Kim called the outlook bright, but the report supplies no comparative data showing which approach works best, for whom, or with what risks. The practical effect will depend on further evidence, regulatory review and the eventual availability of therapies for specific conditions.
remibrutinib for chronic urticaria
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
The AAD Session and Its Scope
The MedPage Today report describes this as only the second CSU-focused session at an AAD meeting since the first such session at the preceding meeting. The discussion took place in Denver, Colorado, and the video was recorded afterward in April. The report was published in October, so its publication date should not be confused with the date of the meeting or recording.
Kim, a professor of dermatology and vice chair of research at Mount Sinai, summarized developments spanning IL-4 receptor, BTK and c-KIT targets. His comments provide an expert overview of topics discussed, rather than a full review of trial evidence. He also disclosed a relevant financial connection: Alys Pharma, which he co-founded, is developing a c-KIT candidate. That disclosure is pertinent when weighing his comments on the approach.
“We spoke a lot about remibrutinib in particular as a hot topic, a recently approved drug, a BTK inhibitor for chronic spontaneous urticaria.”
— Brian Kim
As an affiliate, we earn on qualifying purchases.
Trial Details and Approval Status
The source provides no numerical results, study designs, participant counts or safety data for the phase III CIndU findings. It also does not say whether regulators have reviewed or approved remibrutinib for any CIndU subtype, or give expected timelines for such decisions. Reported phase III data are not the same as an approval, and the article does not establish how the different therapies compare.
For barzolvolimab and the Alys Pharma candidate, the report offers brief descriptions but no complete trial status, results, dosing information or expected launch dates. Kim’s financial disclosure is stated in the source; the article does not provide independent verification of the proposed mechanism or claims of clinical benefit.
As an affiliate, we earn on qualifying purchases.
Evidence and Regulatory Milestones
The next useful developments would be publication of detailed trial data for remibrutinib in CIndU, including results by condition and safety findings, and any subsequent regulatory updates. Further clinical evidence will also be needed to clarify how barzolvolimab and other c-KIT approaches perform and whether the proposed mast-cell targeting translates into patient benefit.
The meeting report does not name a specific upcoming conference, data release or regulatory deadline. Until those details emerge, the therapies should be understood according to their stated status: remibrutinib is reported as approved for CSU, while other findings and candidates remain at different stages of evaluation.
chronic inducible urticaria treatment
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What treatments and targets were discussed?
The session covered remibrutinib, a BTK inhibitor; dupilumab, which blocks the IL-4 receptor; and c-KIT approaches including barzolvolimab and an Alys Pharma candidate.
Is remibrutinib approved for chronic spontaneous urticaria?
The source describes remibrutinib, marketed as Rhapsido, as recently approved for CSU. It does not provide further details about the approval or its conditions of use.
What did the report say about chronic inducible urticaria?
Kim cited reported phase III data for remibrutinib across dermatographism, cold urticaria and cholinergic urticaria. The report does not include numerical results or say that the drug is approved for those conditions.
Are the c-KIT treatments available now?
The article discusses barzolvolimab and an investigational Alys Pharma approach, but does not give their approval status, trial results or availability. It describes the Alys candidate as a development program.
What remains unknown about these approaches?
Detailed efficacy and safety results, comparisons between treatments, CIndU regulatory decisions and timelines for the investigational c-KIT therapies are not provided in the report.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
